Arizona HB2674 prohibits preauthorization and step edit requirements for FDA-approved opioid use disorder medications.
Arizona HB2674 amends the Arizona health care cost containment system to prohibit the administration and its contractors from imposing preauthorization or step edit requirements for FDA-approved medications used to treat opioid use disorder, effective October 1, 2026. This change aims to streamline access to essential treatments for opioid use disorder.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.